Regeneron’s COVID-19 antibody treatment
GPTKB entity
Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:administered_by |
intravenous infusion
high-risk patients healthcare settings adults and children over 12 other supportive treatments |
| gptkbp:approves |
gptkb:U._S._Food_and_Drug_Administration
November 2020 |
| gptkbp:associated_with |
reduced viral load
|
| gptkbp:available_at |
various healthcare providers
|
| gptkbp:available_in |
multiple countries
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:contains |
gptkb:casirivimab
gptkb:imdevimab |
| gptkbp:developed_by |
gptkb:Regeneron_Pharmaceuticals
collaboration with government agencies |
| gptkbp:developed_in_response_to |
gptkb:COVID-19_pandemic
|
| gptkbp:has_received |
positive reviews
|
| https://www.w3.org/2000/01/rdf-schema#label |
Regeneron’s COVID-19 antibody treatment
|
| gptkbp:involves |
combination therapy
|
| gptkbp:involves_administration_of |
two monoclonal antibodies
|
| gptkbp:is_considered |
a key treatment option
a monoclonal antibody cocktail |
| gptkbp:is_designed_to |
preventive use
|
| gptkbp:is_effective_against |
variants resistant to treatment
|
| gptkbp:is_evaluated_by |
post-exposure prophylaxis
efficacy against variants |
| gptkbp:is_part_of |
treatment guidelines
COVID-19 response efforts emergency response to COVID-19 Regeneron’s therapeutic portfolio |
| gptkbp:is_studied_in |
clinical trials
|
| gptkbp:is_subject_to |
ongoing research
|
| gptkbp:is_targeted_at |
gptkb:SARS-Co_V-2
|
| gptkbp:is_used_in |
clinical practice
outpatient settings |
| gptkbp:marketed_as |
gptkb:REGEN-COV
|
| gptkbp:mechanism_of_action |
neutralizing antibodies
|
| gptkbp:not_areplacement_for |
vaccination
|
| gptkbp:part_of |
monoclonal antibody therapies
|
| gptkbp:provided_under |
Emergency Use Authorization
|
| gptkbp:requires |
prescription
|
| gptkbp:shown_to_be_effective_in |
early treatment
|
| gptkbp:shown_to_be_safe_for |
most patients
|
| gptkbp:shown_to_improve |
symptoms
|
| gptkbp:shown_to_reduce |
hospitalization rates
death rates |
| gptkbp:suitable_for |
patients requiring hospitalization
severe COVID-19 cases |
| gptkbp:used_for |
treatment of COVID-19
|
| gptkbp:bfsParent |
gptkb:George_Yancopoulos
|
| gptkbp:bfsLayer |
5
|